Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 4,050 | 8,315 | 44,854 | 8,955 | 17,084 |
| Gross Profit | 4,050 | 8,315 | 44,854 | 8,955 | 17,084 |
| Operating Expenses | 66,827 | 65,834 | 73,434 | 85,233 | 66,669 |
| Operating Income | -62,777 | -57,519 | -28,580 | -76,278 | -49,585 |
| Other Income | 3,812 | 7,982 | 9,081 | 7,510 | 13,241 |
| Pre-tax Income | -58,965 | -49,537 | -19,499 | -68,768 | -36,344 |
| Income Tax | -3,538 | -6,372 | -10,554 | -11,649 | -1,617 |
| Net Income Continuous | -55,427 | -43,165 | -8,945 | -57,119 | -34,727 |
| Net Income | $-55,427 | $-43,165 | $-8,945 | $-57,119 | $-34,727 |
| EPS Basic Total Ops | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| EPS Basic Continuous Ops | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| EPS Diluted Total Ops | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| EPS Diluted Continuous Ops | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.14 | -0.03 | -0.19 | -0.12 |
| EBITDA(a) | $-53,994 | $-48,864 | $-20,660 | $-69,042 | $-42,525 |